english

[Ala81] – MBP (74 – 85)

[Ala81]-MBP (74-85) is a synthetic, modified peptide variant derived from the guinea pig myelin basic protein (MBP) sequence. This research-grade antigen features a precise alanine substitution at position 81, designed to study the effects of specific amino acid changes on immunogenicity and encephalitogenicity. It serves as a specialized tool for dissecting the molecular mechanisms of autoimmune demyelination.

Send Email

Download

TECHNICAL SPECIFICATIONS

Item	Specification
Product Name	[Ala⁸¹]-Myelin Basic Protein (74-85), also known as [Ala81]-MBP (74-85)
CAS NO.	/
Appearance	White to off-white lyophilized powder
Molecular Formula	C55H94N20O21
Molecular Weight	1371.48g/mol
Purity (RP-HPLC)	≥98%
Solubility	Soluble in water, dilute acetic acid, or neutral buffers
Endotoxin	≤10 EU/mg
Biological Activity	A non-encephalitogenic analog of MBP (74-85), used as a control in studies of experimental autoimmune encephalomyelitis
Storage Conditions	Store at -20°C in a dry, sealed container; avoid repeated freeze-thaw cycles.
Stock Location	Stock in USA
MOQ	1g

1.MECHANISM OF ACTION

This modified peptide acts as an altered encephalitogenic epitope. The substitution of alanine at a key residue (position 81) within the core MBP (74-85) sequence modulates its interaction with Major Histocompatibility Complex (MHC) class II molecules and T-cell receptors. This change can either attenuate or, in some contexts, alter the characteristics of the induced autoimmune response, making it a valuable probe for studying antigen processing, MHC binding affinity, and the fine specificity of autoreactive T-cell activation in the Experimental Autoimmune Encephalomyelitis (EAE) model.

2.PRODUCT INDICATIONS

This product is indicated for advanced, hypothesis-driven research in neuroimmunology and autoimmune disease. It is specifically used to investigate the impact of defined amino acid substitutions on antigenicity and pathogenicity in EAE models, to study T-cell receptor recognition and epitope specificity, and to support the rational design of altered peptide ligands (APLs) for potential immunomodulatory therapies targeting diseases like multiple sclerosis.

3.CLINICAL EFFICACY OF PRODUCT

[Ala81]-MBP (74-85) is a preclinical research reagent, not a clinical therapeutic. Its efficacy is defined by its utility as a scientific tool. Studies utilizing this and similar modified peptides have been crucial for proving the concept of "altered peptide ligands" and their potential to modulate T-cell responses. This foundational research has informed the development of APL-based therapeutic strategies for autoimmune diseases, some of which have progressed to clinical trials, highlighting the peptide's role in advancing translational immunology.

4.DELIVERY & SHIPPING

We specialize in global logistics for various cosmetic peptides. Your order will be handled with the utmost care, ensuring safe, reliable, and intact delivery.
Professional and Secure Packaging
Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation.
We can also customize packaging according to customer needs.
Shipping Methods
Main Method: International Air Freight

We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.